Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)
Submitted by MedicalReplies on Thursday, 2 July 2009No Comment
LITTLE FALLS, N.J. (MedPage Today) — The risk of tuberculosis is higher for patients receiving anti-tumor necrosis factor (anti-TNF) monoclonal antibody therapy than for those receiving soluble TNF receptor therapy for any indication, French researchers found.
Here is the original post:
Anti-TNF Therapies Carry Varying Levels of TB Risk (CME/CE)

Leave your response!